The status of gene therapy for brain tumors
- 24 January 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 7 (2), 197-208
- https://doi.org/10.1517/14712598.7.2.197
Abstract
The advent of gene therapy in the early 1990’s raised expectations for brain tumor therapies; however, whereas clinical trials in patients with malignant gliomas provided evidence of safety, therapeutic benefit was not convincing. These early forays resembled the historical introductions of other therapies that seemed promising, only to fail in human trials. Nevertheless, re-study in the laboratory and retesting in iterative laboratory–clinic processes enabled therapies with strong biological rationales to ultimately show evidence of success in humans and become accepted. Examples, such as organ transplantation, monoclonal antibody therapy and antiangiogenic therapy, provide solace that a strategy’s initial lack of success in humans provides an opportunity for its further refinement in the laboratory and development of solutions that will translate into patient success stories. The authors herein summarize results from clinical trials of gene therapy for malignant gliomas, and discuss the influence of these results on present thought in preclinical research.This publication has 116 references indexed in Scilit:
- Serial Passage through Human Glioma Xenografts Selects for a Δγ 1 34.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain TumorsJournal of Virology, 2006
- Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus VectorCancer Research, 2006
- Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and MetastasisCell, 2006
- Adeno-associated virus vectors: potential applications for cancer gene therapyCancer Gene Therapy, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5JCI Insight, 2002
- Molecular Imaging of Gene Expression and Efficacy following Adenoviral-Mediated Brain Tumor Gene TherapyMolecular Imaging, 2002
- A Herpes Simplex Virus Type 1 γ34.5 Second-Site Suppressor Mutant That Exhibits Enhanced Growth in Cultured Glioblastoma Cells Is Severely Attenuated in AnimalsJournal of Virology, 2001
- p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastomaOncogene, 2000
- Expression and activity of human Na+/I− symporter in human glioma cells by adenovirus-mediated gene deliveryGene Therapy, 2000